US Edition
Surgery Leads to 5 Times Greater Weight Loss Than Ozempic, New Research Reveals
9 Articles
9 Articles
One Weight Loss Strategy Is 5x More Effective Than Ozempic, Trials Show
Ozempic and other semaglutide medications have been working wonders in terms of shedding pounds for many people, but a new study shows that they're still not as effective as surgery when it comes to weight loss – and it's not even close.
Surgery Leads to 5 Times Greater Weight Loss Than Ozempic, New Research Reveals
GLP-1 weight-loss drugs like Ozempic and Wegovy have been hailed as nothing short of miracle workers for their ability to help people shed pounds quickly and efficiently. These injectable medications have surged in popularity so much that it's estimated that 12 percent of U.S. adults have tried such a drug. At the same time, and likely because of this, data shows that demand for bariatric surgery has plunged, dropping nearly 26 percent in 2023.H…
Sunderland bariatrics expert honoured for collaborative research in Spain
An academic from the University of Sunderland has been recognised for her contribution to the field of metabolic and bariatric surgery in Spain.Professor Yitka Graham has been awarded Honorary Membership of the Spanish Society for Surgery of Obesity and Metabolic Disorders (SECO) in recognition of her collaborative work on research projects focusing on innovative ways to improve the care and experience of people living with metabolic and bariatr…
Ozempic and Wegovy owe a lot to Hollywood, where it was discovered that you can radically lose weight with semaglutide-based drugs - but its beneficial effect on addictions was also revealed by the stars. A lot of research has been launched to find out why drugs developed for diabetes work against many diseases.
Weight-loss surgery trumps popular Ozempic treatment in shocking new comparison - Daily news Update
NEWYou can now listen to Fox News articles! Weight-loss surgery was shown to be five times more effective than weekly injections of popular GLP-1 receptor agonists, including semaglutide (such as Ozempic) and tirzepatide (such as Mounjaro). The finding comes from a recent study presented this week at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting in Washington. Researchers looked at “real-world” e…
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
